TY - JOUR
T1 - Caring for Hospitalized Patients with Diabetes Mellitus, Hyperglycemia, and COVID-19
T2 - Bridging the Remaining Knowledge Gaps
AU - Wallia, Amisha
AU - Prince, Grace
AU - Touma, Emilie
AU - El Muayed, Malek
AU - Seley, Jane Jeffrie
N1 - Funding Information:
Amisha Wallia is a section editor for Current Diabetes Reports and recieves grant funding from Novo Nordisk, and research salary support from United Health Group and Eli Lilly. Grace Prince, Emilie Touma, and Malek El Muayed each declare no potential conflicts of interest. Jane Jeffrie Seley is a section editor for Current Diabetes Reports.
Publisher Copyright:
© 2020, Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2020/12
Y1 - 2020/12
N2 - Purpose of Review: This review discusses the interplay between coronavirus disease 2019 (COVID-19, caused by SARS-CoV-2 infection), diabetes mellitus, and hyperglycemia in the hospital setting. There are data emerging about diabetes and hyperglycemia, their prevalence, and potential risks in the setting of SARS-CoV-2 infection and COVID-19. Recent Findings: It is known that viral infections exert effects on beta cell function and insulin resistance. Therefore, much can be learned about SARS-CoV-2/COVID-19 from examining these known relationships. Such pathophysiological underpinnings may unlock greater understanding as we navigate atypical cases of hyperglycemia, severe insulin resistance, and diabetic ketoacidosis amidst COVID-19. Glycemic outcomes likely have beneficial effects on morbidity and mortality, but this needs to be studied. Summary: Changes in diabetes-related protocols and new technology can be deployed in the inpatient setting to potentially improve healthcare worker and patient safety; however, one must weigh the risks and benefits of implementation during a pandemic. Ultimately, knowledge and research must be shared at record speed to combat this global crisis.
AB - Purpose of Review: This review discusses the interplay between coronavirus disease 2019 (COVID-19, caused by SARS-CoV-2 infection), diabetes mellitus, and hyperglycemia in the hospital setting. There are data emerging about diabetes and hyperglycemia, their prevalence, and potential risks in the setting of SARS-CoV-2 infection and COVID-19. Recent Findings: It is known that viral infections exert effects on beta cell function and insulin resistance. Therefore, much can be learned about SARS-CoV-2/COVID-19 from examining these known relationships. Such pathophysiological underpinnings may unlock greater understanding as we navigate atypical cases of hyperglycemia, severe insulin resistance, and diabetic ketoacidosis amidst COVID-19. Glycemic outcomes likely have beneficial effects on morbidity and mortality, but this needs to be studied. Summary: Changes in diabetes-related protocols and new technology can be deployed in the inpatient setting to potentially improve healthcare worker and patient safety; however, one must weigh the risks and benefits of implementation during a pandemic. Ultimately, knowledge and research must be shared at record speed to combat this global crisis.
KW - Covid-19
KW - Diabetes
KW - Hyperglycemia
KW - Inpatient management
KW - SARS-CoV2
UR - http://www.scopus.com/inward/record.url?scp=85096800099&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85096800099&partnerID=8YFLogxK
U2 - 10.1007/s11892-020-01366-0
DO - 10.1007/s11892-020-01366-0
M3 - Review article
C2 - 33244614
AN - SCOPUS:85096800099
SN - 1534-4827
VL - 20
JO - Current Diabetes Reports
JF - Current Diabetes Reports
IS - 12
M1 - 77
ER -
